Baseline TNF‐α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease

OBJECTIVES: Crohn's disease (CD) is a systemic disorder in which conventional luminal endoscopic assessments may incompletely reflect overall inflammatory burden. We aimed to evaluate the associations between baseline inflammatory cytokines, disease phenotype, infliximab (IFX) pharmacokinetics, and the need for dose intensification (DI) in pediatric CD. METHODS: This prospective study included pediatric patients with moderate-to-severe CD treated with IFX. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels were measured at diagnosis. Baseline imbalances were adjusted using propensity score matching and inverse probability of treatment weighting analyses. RESULTS: Of the 160 enrolled patients, 15 (9.4%) were not included in the 1-year analysis, and 145 (90.6%) completed the 1-year follow-up. Body mass index (BMI)-adjusted TNF-α levels correlated with erythrocyte sedimentation rate (R = 0.22, p = 0.008) and fecal calprotectin (R = 0.34, p < 0.001), but not with simple endoscopic score for CD. In contrast, IL-6 levels were not significantly associated with inflammatory biomarkers. Cytokine profiles and IFX trough levels were not associated with perianal disease status or disease location. DI was required in 94 of 145 patients (64.8%), and patients requiring DI demonstrated higher baseline TNF-α levels than those without DI (49.63 ± 29.09 vs. 40.14 ± 16.59 pg/mL, p = 0.046). CONCLUSIONS: Higher baseline TNF-α levels were associated with subsequent IFX DI, while also correlating with conventional inflammatory biomarkers but not with SES-CD or anatomical disease phenotype. These findings suggest that baseline TNF-α may reflect an aspect of inflammatory burden relevant to subsequent treatment requirements that is not captured by luminal endoscopic severity or anatomical disease classification alone.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Gastroenterology and Nutrition
Published
2026-11-17
DOI
https://doi.org/10.1002/jpn3.70684
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Baseline TNF‐α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease

Yiyoung Kwon, Tae Jong Jeong, Yon Ho Choe, Yoon Zi Kim et al.
2 links
Journal of Pediatric Gastroenterology and Nutrition
Inflammatory Bowel Disease
article

Baseline TNF‐α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease

Yiyoung Kwon, Tae Jong Jeong, Yon Ho Choe, Yoon Zi Kim, Eun Sil Kim, Mi Jin Kim
article en

Abstract

OBJECTIVES: Crohn's disease (CD) is a systemic disorder in which conventional luminal endoscopic assessments may incompletely reflect overall inflammatory burden. We aimed to evaluate the associations between baseline inflammatory cytokines, disease phenotype, infliximab (IFX) pharmacokinetics, and the need for dose intensification (DI) in pediatric CD. METHODS: This prospective study included pediatric patients with moderate-to-severe CD treated with IFX. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels were measured at diagnosis. Baseline imbalances were adjusted using propensity score matching and inverse probability of treatment weighting analyses. RESULTS: Of the 160 enrolled patients, 15 (9.4%) were not included in the 1-year analysis, and 145 (90.6%) completed the 1-year follow-up. Body mass index (BMI)-adjusted TNF-α levels correlated with erythrocyte sedimentation rate (R = 0.22, p = 0.008) and fecal calprotectin (R = 0.34, p < 0.001), but not with simple endoscopic score for CD. In contrast, IL-6 levels were not significantly associated with inflammatory biomarkers. Cytokine profiles and IFX trough levels were not associated with perianal disease status or disease location. DI was required in 94 of 145 patients (64.8%), and patients requiring DI demonstrated higher baseline TNF-α levels than those without DI (49.63 ± 29.09 vs. 40.14 ± 16.59 pg/mL, p = 0.046). CONCLUSIONS: Higher baseline TNF-α levels were associated with subsequent IFX DI, while also correlating with conventional inflammatory biomarkers but not with SES-CD or anatomical disease phenotype. These findings suggest that baseline TNF-α may reflect an aspect of inflammatory burden relevant to subsequent treatment requirements that is not captured by luminal endoscopic severity or anatomical disease classification alone.

Journal of Pediatric Gastroenterology and Nutrition
Samsung Medical Center (KR), Kangbuk Samsung Hospital (KR), Sungkyunkwan University (KR)
Korea Health Industry Development Institute
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon